Recent developments in sterol 14-demethylase inhibitors for Chagas disease

International Journal for Parasitology: Drugs and Drug Resistance

Volumn 2, Issue , 2012, Pages 236-242

  Buckner, Frederick S ^a   Urbina, Julio A ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^c NONE   (United States)

Author keywords

Chagas disease; Cyp51; Sterol 14 demethylase; Trypanosoma cruzi

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; ALBACONAZOLE; BENZNIDAZOLE; CLOTRIMAZOLE; E 1224; ECONAZOLE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NIFURTIMOX; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; SDZ 285604; STEROL 14ALPHA DEMETHYLASE; STEROL 14ALPHA DEMETHYLASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG; VORICONAZOLE;

AMASTIGOTE; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CHAGAS DISEASE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION PREVENTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STEROL ANALYSIS; STEROL SYNTHESIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TRYPANOSOMA CRUZI; UNSPECIFIED SIDE EFFECT;

EID: 84871574115     PISSN: 22113207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpddr.2011.12.002     Document Type: Review

References (48)

1. Apt, W., Aguilera, X., Arribada, A., Perez, C., Miranda, C., Sanchez, G., Zulantay, I., Cortes, P., Rodriguez, J., Juri, D., 1998. Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am. J. Trop. Med. Hyg. 59, 133-138
2. Bahia, M.T. 2011. Anti-T. cruzi activities of benznidazole and posaconazole, used alone or in combination, in a murine model of acute Chagas disease. 27th Meeting on Applied Research on Chagas Disease, Uberaba, MG, Brazil
3. Buckner, F., Yokoyama, K., Lockman, J., Aikenhead, K., Ohkanda, J., Sadilek, M., Sebti, S., Van Voorhis, W., Hamilton, A., Gelb, M.H., 2003. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc. Natl. Acad. Sci USA 100, 15149-15153
4. Buckner, F.S., 2008. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. Adv. Exp. Med. Biol. 625, 61-80
5. Campoli, P., Al Abdallah, Q., Robitaille, R., Solis, N.V., Fielhaber, J.A., Kristof, A.S., Laverdiere, M., Filler, S.G., Sheppard, D.C., 2011. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob. Agents Chemother. 55, 5732-5739
6. Chen, C.K., Doyle, P.S., Yermalitskaya, L.V., Mackey, Z.B., Ang, K.K., McKerrow, J.H., Podust, L.M., 2009. Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Negl. Trop. Dis. 3, e372
7. Chen, C.K., Leung, S.S., Guilbert, C., Jacobson, M.P., McKerrow, J.H., Podust, L.M., 2010. Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl. Trop. Dis. 4, e651
8. Clayton, J., 2010. Chagas Disease: Pushing Through the Pipeline. Nature 465, S12-S15
9. Corrales, M., Cardozo, R., Segura, M.A., Urbina, J.A., Basombrio, M.A., 2005 Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob. Agents Chemother. 49, 1556-1560
10. Daum, G., Lees, N.D., Bard, M., Dickson, R., 1998. Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Yeast 14, 1471-1510
11. Diniz, L.F., Caldas, I.S., Guedes, P.M., Crepalde, G., de Lana, M., Carneiro, C.M., Talvani, A., Urbina, J.A., Bahia, M.T., 2010. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob. Agents Chemother. 54, 2979-2986
12. Docampo, R., 1981. Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Mol. Biochem. Parasitol. 3, 169-180
13. Doyle, P.S., Chen, C.K., Johnston, J.B., Hopkins, S.D., Leung, S.S., Jacobson, M.P., Engel, J.C., McKerrow, J.H., Podust, L.M., 2010. A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Antimicrob. Agents Chemother. 54, 2480-2488
14. Fischer, R.T., Stam, S.H., Johnson, P.R., Ko, S.S., Magolda, R.L., Gaylor, J.L., Trzaskos, J.M., 1989. Mechanistic studies of lanosterol 14 alpha-methyl demethylase: substrate requirements for the component reactions catalyzed by a single cytochrome P-450 isozyme. J. Lipid Res. 30, 1621-1632
15. Furlong, S.T., 1989. Sterols of parasitic protozoa and helminths. Exp. Parasitol. 68, 482-485
16. Gascon, J., Bern, C., Pinazo, M.J., 2010. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 115, 22-27
17. Guedes, P.M., Urbina, J.A., de Lana, M., Afonso, L.C., Veloso, V.M., Tafuri, W.L., Machado-Coelho, G.L., Chiari, E., Bahia, M.T., 2004. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob. Agents Chemother. 48, 4286-4292
18. Hargrove, T.Y., Wawrzak, Z., Liu, J., Waterman, M.R., Nes, W.D., Lepesheva, G.I., 2011 Structural complex of sterol 14alpha-demethylase (CYP51) with 14alphamethylenecyclopropyl-D7-24, 25-dihydrolanosterol. J. Lipid Res. (Epub ahead of print)
19. Hucke, O., Gelb, M.H., Verlinde, C.L., Buckner, F.S., 2005. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J. Med. Chem. 48, 5415-5418
20. Konkle, M.E., Hargrove, T.Y., Kleshchenko, Y.Y., von Kries, J.P., Ridenour, W., Uddin, M.J., Caprioli, R.M., Marnett, L.J., Nes, W.D., Villalta, F., Waterman, M.R., Lepesheva, G.I., 2009. Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. J. Med. Chem. 52, 2846-2853
21. Korn, E.D., Von Brand, T., Tobie, E.J., 1969. The sterols of Trypanosoma cruzi and Crithidia fasciculata. Comp. Biochem. Physiol. 30, 601-610
22. Kraus, J.M., Verlinde, C.L., Karimi, M., Lepesheva, G.I., Gelb, M.H., Buckner, F.S., 2009 Rational modification of a candidate cancer drug for use against Chagas disease J. Med. Chem. 52, 1639-1647
23. Kraus, J.M., Tatipaka, H.B., McGuffin, S.A., Chennamaneni, N.K., Karimi, M., Arif, J., Verlinde, C.L., Buckner, F.S., Gelb, M.H., 2010. Second generation analogues of the cancer drug clinical candidate Tipifarnib for anti-chagas disease drug discovery. J. Med. Chem. 53, 3887-3898
24. Lepesheva, G.I., Zaitseva, N.G., Nes, W.D., Zhou, W., Arase, M., Liu, J., Hill, G.C., Waterman, M.R., 2006. CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase. J Biol. Chem. 281, 3577-3585
25. Lepesheva, G.I., Ott, R.D., Hargrove, T.Y., Kleshchenko, Y.Y., Schuster, I., Nes, W.D., Hill, G.C., Villalta, F., Waterman, M.R., 2007. Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chem. Biol. 14, 1283-1293
26. Lepesheva, G.I., Hargrove, T.Y., Anderson, S., Kleshchenko, Y., Furtak, V., Wawrzak, Z., Villalta, F., Waterman, M.R., 2010a. Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi. J. Biol. Chem 285, 25582-25590
27. Lepesheva, G.I., Hargrove, T.Y., Kleshchenko, Y., Nes, W.D., Villalta, F., Waterman, M.R., 2008. CYP51: a major drug target in the cytochrome P450 superfamily Lipids 43, 1117-1125
28. Lepesheva, G.I., Park, H.W., Hargrove, T.Y., Vanhollebeke, B., Wawrzak, Z., Harp, J.M., Sundaramoorthy, M., Nes, W.D., Pays, E., Chaudhuri, M., Villalta, F., Waterman, M.R., 2010b. Crystal structures of Trypanosoma brucei sterol 14alphademethylase and implications for selective treatment of human infections. J Biol. Chem. 285, 1773-1780
29. Lepesheva, G.I., Villalta, F., Waterman, M.R., 2011. Targeting Trypanosoma cruzi sterol 14alpha-demethylase (CYP51). Adv. Parasitol. 75, 65-87
30. Leslie, M., 2011. Infectious diseases. A tropical disease hits the road. Science 333, 934
31. Liendo, A., Lazardi, K., Urbina, J.A., 1998. In-vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(_) enantiomer against Trypanosoma cruzi. J. Antimicrob. Chemother. 41, 197-205
32. Liendo, A., Visbal, G., Piras, M.M., Piras, R., Urbina, J.A., 1999. Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol. Biochem. Parasitol. 104, 81-91
33. Marin-Neto, J.A., Cunha-Neto, E., Maciel, B.C., Simoes, M.V., 2007. Pathogenesis of chronic Chagas heart disease. Circulation 115, 1109-1123
34. Molina, J., Martins-Filho, O., Brener, Z., Romanha, A.J., Loebenberg, D., Urbina, J.A., 2000. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother. 44, 150-155
35. Pinazo, M.J., Espinosa, G., Gallego, M., Lopez-Chejade, P.L., Urbina, J.A., Gascon, J., 2010. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am. J. Trop. Med. Hyg. 82, 583-587
36. Rassi Jr., A., Rassi, A., Marin-Neto, J.A., 2010. Chagas disease. Lancet 375, 1388-1402
37. Urbina, J., 2011. New insights in Chagas's disease treatment. Drug Future 35, 409-419
38. Urbina, J.A., 2010. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 115, 55-68
39. Urbina, J.A., Docampo, R., 2003. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 19, 495-501
40. Urbina, J.A., Payares, B., Molina, J., Sanoja, C., Liendo, A., Lazardi, K., Piras, M.M., Piras, R., Wincker, P., Ryley, J.F., 1996. Cure of short- and long-term experimental Chagas' disease using D0870. Science 273, 969-971
41. Urbina, J.A., Payares, G., Contreras, L.M., Liendo, A., Sanoja, C., Molina, J., Piras, M., Piras, R., Perez, N., Wincker, P., Loebenberg, D., 1998. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Agents Chemother. 42, 1771-1777
42. Urbina, J.A., Payares, G., Sanoja, C., Lira, R., Romanha, A.J., 2003a. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents 21, 27-38
43. Urbina, J.A., Payares, G., Sanoja, C., Molina, J., Lira, R., Brener, Z., Romanha, A.J., 2003b. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drugresistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents 21, 39-48
44. Urbina, J.A., Concepcion, J.L., Caldera, A., Payares, G., Sanoja, C., Otomo, T., Hiyoshi, H., 2004. In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi Antimicrob. Agents Chemother. 48, 2379-2387
45. Viotti, R., Vigliano, C., Lococo, B., Bertocchi, G., Petti, M., Alvarez, M.G., Postan, M., Armenti, A., 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern. Med. 144, 724-734
46. Viotti, R., Vigliano, C., Alvarez, M.G., Lococo, B., Petti, M., Bertocchi, G., Armenti, A., De Rissio, A.M., Cooley, G., Tarleton, R., Laucella, S., 2011. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease PLoS Negl. Trop. Dis. 5, e1314
47. Walker, K.A., Kertesz, D.J., Rotstein, D.M., Swinney, D.C., Berry, P.W., So, O.Y., Webb, A.S., Watson, D.M., Mak, A.Y., Burton, P.M., 1993. Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering. J. Med. Chem. 36, 2235-2237
48. Williams, K.J., Denning, D.W., 2001. Termination of development of D0870. J Antimicrob. Chemother. 47, 720-721